| Literature DB >> 31234352 |
Abstract
Here, the constituents of coffee with estrogenic activity are summarized by a comprehensive literature search, and their mechanisms of action for their physiological effects are discussed at the molecular and cellular levels. The estrogenic activity of coffee constituents, such as acids, caramelized products, carbohydrates, lignin, minerals, nitrogenous compounds, oil (lipids), and others, such as volatile compounds, was first evaluated by activity assays, such as animal tests, cell assay, ligand-binding assay, protein assay, reporter-gene assay, transcription assay, and yeast two-hybrid assay. Second, the health benefits associated with the estrogenic coffee constituents, such as bone protection, cancer treatment/prevention, cardioprotection, neuroprotection, and the improvement of menopausal syndromes, were summarized, including their potential therapeutic/clinical applications. Inconsistent results regarding mixed estrogenic/anti-estrogenic/non-estrogenic or biphasic activity, and unbeneficial effects associated with the constituents, such as endocrine disruption, increase the complexity of the effects of estrogenic coffee constituents. However, as the increase of the knowledge about estrogenic cell signaling, such as the types of specific signaling pathways, selective modulations of cell signaling, signal crosstalk, and intercellular/intracellular networks, pathway-based assessment will become a more realistic means in the future to more reliably evaluate the beneficial applications of estrogenic coffee constituents.Entities:
Keywords: coffee constituents; estrogen assay; estrogenicity; phytoestrogens; signal transduction pathway
Year: 2019 PMID: 31234352 PMCID: PMC6628280 DOI: 10.3390/nu11061401
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
List of major coffee constituents.
| Chemical | Amount (%w/w) | ||
|---|---|---|---|
| Green a | Roasted a | Roasted b | |
|
| |||
| Chlorogenic acids | 5.5–8.0 | 1.2–2.3 | 2.5 |
| Quinic acid | 0.7 | ||
| Aliphatic acids (citric acid, malic acid, lactic acid, acetic acid, etc.) | 1.5–2.0 | 1.0–1.5 | 1.5 |
|
| 0 | 16.0–17.0 | 23.2 |
| Humic acids, melanoidins, etc. | |||
|
| |||
| Sucrose | 0 | ||
| Reducing sugars (glucose, fructose, arabinose, etc.) | 0.3 | ||
| Polysaccharides (glucan, galactan, araban, mannan, etc.) | 50.0–55.0 | 24.0–39.0 | 32.0 |
| Pectin (galacturonon) | 3.0 | ||
|
| 2.0 | ||
|
| 3.0–4.2 | 3.5–4.5 | 5.0 |
| K, Ca2+, Mg2+, etc. | |||
|
| |||
| Alkaloids (caffeine, theobromine, theophylline, etc.) | 0.9–1.2 | ~1.0 | 1.4 |
| Amino acid | 2.0 | 0 | 0 |
| Nicotinic acid | 0.015 | ||
| Protein | 11.0–13.0 | 13.0–15.0 | 10.0 |
| Trigonelline | 1.0–1.2 | 0.5–1.2 | 0.4 |
| Others (choline, serotonin amides, etc.) | |||
|
| 12.0–18.0 | 14.5–20.0 | 18.0 |
| Diterpene alcohols/esters, phosphatides, sterols, tocopherols, triglycerides, | |||
| Tryptamine derivatives, etc. | |||
|
| |||
| Volatile compounds (pyridines, quinolines, pyrazines, pyrroles, etc.) | 0.1 | ||
The list of chemicals was made from the information in Clarke (1987) [4] and Viani (1988) [7], where typical compositions of green and roasted arabica coffee are shown (a Smith, 1985 [8]; b Clarke, 1987 [4]). The chemicals included in the respective category are detailed in Clifford (1985) [9] (chlorogenic acid), Woodman (1985) [10] (aliphatic acids), Trugo (1985) [11] (carbohydrates), Clarke (1985) [12] (minerals), Macrae (1985) [13] (nitrogenous compounds), Folstar (1985) [14] (oil), and Dart and Nursten (1985) [15] (volatile compounds).
Assays used to detect estrogenic activity.
| Assay Category (Symbol)/Description | Example a |
|---|---|
|
| |
| Animal tests quantitate reproductive, developmental and behavioral effects in animals. | Medaka assay |
| Zebrafish assay | |
| Rainbow trout assay | |
| Rodent uterotrophic assay | |
|
| |
| Cell assays quantitate cell growth and proliferation. | Cell counter assay |
| Cell density/viability assay (SRB assay/AlamarBlue assay/MTS assay/MTT assay/WST-8 assay) | |
| Dye exclusion method (Trypan blue assay) | |
| E-screen assay | |
| Flow cytometry | |
|
| |
| Ligand-binding assays quantitate the receptor–ligand interaction. | Assay with ERs in cells |
| Assay with ERs in tissues (uterus, etc.) | |
| Assay with recombinant ERs | |
| Assay with Venus fluorescent protein | |
| Competitive enzyme immunoassay | |
| Fluorescence polarization assay | |
| Molecular docking | |
| QSAR | |
|
| |
| Protein assays quantitate protein amounts and functions. | ChIP assay |
| ELISA | |
| Immunoassay (ICC, IHC) | |
| Western blotting (ERα/ERβ) | |
| Western blotting (Akt/ERK) | |
|
| |
| Reporter-gene assays quantitate the transcription upon ligand-dependent binding of the receptor to an estrogen response element on DNA. | CALUX assay |
| GFP-based assay | |
| Luciferase-based assay | |
| MVLN cell assay | |
| YES assay | |
|
| |
| Transcription assays quantitate the transcription of ER or marker genes. | DNA microarray assay |
| Northern blotting | |
| RT-PCR | |
|
| |
| Yeast two-hybrid assays quantitate the ligand-dependent interaction between the receptor and the transcriptional activator. | GAL4-based assay |
| Whole hERα-based assay |
a The examples are adapted from Kiyama (2017) [37]. For details of estrogenic chemicals analyzed by each assay, see Kiyama and Wada-Kiyama (2015) [35]. Abbreviations: CALUX: chemically activated luciferase expression; ChIP: chromatin immunoprecipitation; ELISA: enzyme-linked immunosorbent assay; ER: estrogen receptor; ERK: extracellular signal-regulated kinase; GFP: green fluorescent protein; ICC: immunocytochemistry; IHC: immunohistochemistry; MTS: (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium); MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; QSAR: quantitative structure-activity relationship; RT-PCR: reverse transcription polymerase chain reaction; SRB: sulforhodamine B; WST-8: (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium); YES: yeast estrogen screen.
Estrogenic coffee constituents.
| Chemical | Receptor/Pathway | Estro-Genicity a | Function or Subject | Reference (Assay b) |
|---|---|---|---|---|
|
| ||||
| Caffeic acid | ER | E | Menopausal syndrome/Obesity | Zych et al., 2009 [ |
| Caffeic acid | ER | E/A | Bone protection | Folwarczna et al., 2015 [ |
| Caffeic acid | ER | N | Breast cancer/Chemoprevention | Nunes et al., 2017 [ |
| Caffeic acid phenethyl ester | ERβ | S | Menopausal syndrome | Jung et al., 2010 [ |
| Caffeic acid phenethyl ester | ERα/β (crosstalk) | S | Prostate cancer/Chemoprevention | Tolba et al., 2013 [ |
| Caffeic acid/Ferulic acid derivatives | ER | A | Breast cancer/Chemoprevention | Serafim et al., 2011 [ |
| Chlorogenic acid | ER | N | Menopausal syndrome | Innocenti et al., 2007 [ |
| Chlorogenic acid | ER | E/N | Bone protection | Folwarczna et al., 2009 [ |
| Chlorogenic acid | ERβ | E | Osteoporosis/Bone protection | Zhou et al., 2016 [ |
| Cinnamic acid esters | ER | A | Breast cancer/Chemoprevention | Hostanska et al., 2004 [ |
| Cinnamic acid (moiety) | ERα | S | Breast cancer/Chemoprevention | Kieser et al., 2010 [ |
| Ferulic acid | ERα (crosstalk) | E | Breast cancer/Chemoprevention | Chang et al., 2006 [ |
| Ferulic acid | ER | N | Menopausal syndrome | Wen et al., 2011 [ |
| Ferulic acid | ERα | E | Breast cancer/Chemoprevention | Belkaid et al., 2016 [ |
| Ferulic acid/Isoferulic acid | ER | E | Menopausal syndrome | Stromeier et al., 2005 [ |
| Gallate (Octyl) | ERα | E | Alzheimer’s disease | Zhang et al., 2013 [ |
| Gallic acid | ER | N | Endocrine disruption | Miller et al., 2001 [ |
| Gallic acid | ERα/β | N | Phytoestrogen/Health benefits | Mallavadhani et al., 2006 [ |
| Hippuric acid | ER | E | Endocrine disruption | Picard et al., 2001 [ |
| Sinapic acid | ER | E | Metabolic disorders | Zych et al., 2018 [ |
| Vanillic acid | ERα/β | E | Osteoporosis/Bone protection | Xiao et al., 2014 [ |
| Vanillic acid | ERα | A | Benign prostatic hyperplasia | Jung et al., 2017 [ |
|
| ||||
| Humic acids | ER | A | Endocrine disruption | Janosek et al., 2007 [ |
| Humic acids | ER | A | Endocrine disruption | Tang et al., 2014 [ |
| Humic acids | ER | A | Endocrine disruption | Bedard et al., 2014 [ |
| Humic substance (synthetic) | ER | E | Endocrine disruption | Lutz et al., 2005 [ |
|
| ||||
| None | ||||
|
| ||||
| Lignin | ER | A | Enterohepatic circulation | Arts et al., 1991 [ |
| Lignin (methanol) | ER | N | Endocrine disruption | Nakamura et al., 2001 [ |
|
| ||||
| Caffeine | ER (crosstalk) | A | Parkinson’s disease | Xu et al., 2006 [ |
| Caffeine | ERα (crosstalk) | A | Breast cancer/Chemoprevention | Rosendahl et al., 2015 [ |
| Nicotinic acid (Niacin) | GPER | E | Cardioprotection | Santolla et al., 2014 [ |
| Serotonin | GPER (crosstalk) | E | Depressive disorder | Li et al., 2013 [ |
| Theophylline | ER | E | Estrogenic response | Steinsapir et al., 1982 [ |
| Theophylline derivative (TPBM) | ERα | A | Breast cancer/Chemoprevention | Mao et al., 2008 [ |
| Trigonelline | ER | E | Carcinogenesis/Phytoestrogen | Allred et al., 2009 [ |
| Trigonelline | ER | E/A | Bone protection | Folwarczna et al., 2014 [ |
| Trigonelline | ER | E | Colon cancer/Chemoprevention | Yoo and Allred, 2016 [ |
|
| ||||
| Campesterol/β-Sito-sterol/Stigmasterol | ER | N | Endocrine disruption | Baker et al., 1999 [ |
| Campesterol/β-Sito-sterol/Stigmasterol | ERα | N | Endocrine disruption | Procházková et al., 2017 [ |
| Citrostadienol | ER | N | Reproductive dysfunction | Mellanen et al., 1996 [ |
| Lecithin (soy) | ERα | E | Endocrine disruption | Behr et al., 2011 [ |
| β-Sitosterol | ER | B | Feminization | Rosenblum et al., 1993 [ |
| β-Sitosterol | ERα/β | E | Endocrine disruption | Gutendorf and Westendorf, 2001 [ |
| β-Sitosterol | ER | E | Breast cancer/Chemoprevention | Ju et al., 2004 [ |
| β-Sitosterol | ER | N | Cell proliferation | Shappell et al., 2012 [ |
| β-Sitosterol | ERα | E | Alzheimer’s disease | Shi et al., 2013 [ |
| Stigmastanol | ER | N | Endocrine disruption | Monteverdi and Di Giulio, 1999 [ |
| Stigmasterol | ER | E | Estrogen replacement therapy | Boldrin et al., 2013 [ |
| γ-Tocopherol (mixture) | ERα | A | Cancer/Chemoprevention | Smolarek et al., 2013 [ |
| γ/δ-Tocopherol | ER | A | Cancer/Chemoprevention | Bak et al., 2017 [ |
| γ/δ-Tocotrienol | ERβ | E | Cancer/Chemoprevention | Comitato et al., 2009 [ |
| δ-Tocotrienol | ERβ | E | Parkinson’s disease | Nakaso et al., 2016 [ |
|
| ||||
| Coffee extract (ethanol) | ER | E | Endocrine disruption | Kitts, 1987 [ |
| Coffee extract (80% methanol) | ER | E | Endocrine disruption | Takamura-Enya et al., 2003 [ |
| Diazenes | ERα/β | S | Breast cancer/Chemoprevention | Ghosh et al., 2003 [ |
Chemicals include derivatives of the chemicals listed and those found in green coffee. The categories listed are shown in Table 1. a Activity: anti-estrogenic (A), biphasic (B), estrogenic (E), not estrogenic (N), or SERM (S). b Abbreviations for the assays used to detect estrogenic activity are: animal test (A), cell assay (C), ligand-binding assay (L), protein assay (P), reporter-gene assay (R), transcription assay (T), and yeast two-hybrid assay (Y) (see Table 2). ER: estrogen receptor; GPER: G protein-coupled estrogen receptor 1; SERM: selective estrogen receptor modulator.
Figure 1Structure of estrogenic coffee constituents.
Applications and physiological effects of estrogenic coffee constituents.
|
|
| Caffeic acid, chlorogenic acid, vanillic acid |
|
|
| Caffeic acid phenethyl ester, caffeic acid/ferulic acid derivatives, caffeine, cinnamic acid esters, |
|
|
| Nicotinic acid (niacin) |
|
|
| Coffee extract, hippuric acid, humic acids, lecithin, β-sitosterol |
|
|
| Caffeic acid, caffeic acid phenethyl ester, ferulic acid/isoferulic acid, sinapic acid, stigmasterol, theophylline |
|
|
| Caffeine, gallate (octyl), serotonin, β-sitosterol, δ-tocotrienol |
Note that chemicals are listed in a representative category (see Table 3).